drugset
drugset / Trial / NCT04182191

Influence of CYP2C9 Genotype on Clinical Efficacy of Tenoxicam

NCT04182191 ↗

Phase 4 Completed 89 enrolled University of Sao Paulo
NaSingle-groupOpen-labelSupportive care

Summary

The goal of this study is to evaluate the different gene haplotypes for the clinical efficacy of tenoxicam after third lower molar surgery for pain, edema and trismus, adverse reactions, need of rescue medication, patient satisfaction regarding the drug and the pharmacokinetics of the drug between the different gene haplotypes for CYP2C9 that are found in this population

Timeline

Start
2018-03-01
Primary completion
2019-07-01
Completion
2019-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenoxicam Other / unclassified 20 mg —

Indications

No indication recorded.